Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CYP2C19 Genotype-GUided Dual Antiplatelet theRapy in pAtieNts Treated With New Generation Drug Eluting stEnts (the GUARANTEE Study)

NCT03783351 is registered in ClinicalTrials.gov with Beijing Anzhen Hospital as lead sponsor.

NCT NCT03783351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03783351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CYP2C19 Genotype-GUided Dual Antiplatelet theRapy in pAtieNts Treated With New Generation Drug Eluting stEnts (the GUARANTEE Study)
Lead sponsor
Beijing Anzhen Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
May 27, 2019
Completion date
April 30, 2026
Enrollment
4,009 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, angina, stable, drug-eluting stents, genotype